AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17237130
Drug: Metoprolol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (n = 1518, target dose 100 mg daily)
Trial: 11352444
Drug: Theophylline 400mg
RxNorm normalized name: THEOPHYLLINE 400MG TAB,SA
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 400mg alone (Treatment B)
Trial: 11352444
Drug: Theophylline 400mg
RxNorm normalized name: THEOPHYLLINE 400MG TAB,SA
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 400mg plus moxifloxacin 200mg (Treatment C)
Trial: 11352444
Drug: Moxifloxacin 200mg
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 200mg alone (Treatment A)
Trial: 9797810
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with autologous stem cell rescue
Trial: 9797810
Drug: HDCT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCT in first-line therapy for poor-risk GCTs
Trial: 28870554
Drug: Conventional professional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional professional based speech language therapy (SLT) alone (Group A/less intensive)
Trial: 28870554
Drug: Conventional professional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional professional based speech language therapy (SLT) assisted by computer based language therapy software (Group B/more intensive)
Trial: 23416804
Drug: Peppermint oil,
RxNorm normalized name: Peppermint Oil, NF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil, administered three times daily for six weeks
Trial: 23416804
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered three times daily for six weeks
Trial: 15673985
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort extract (SJW) 600 mg (standardized to contain 1800 microg of hypericin)
Trial: 11408053
Drug: Dual-task performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-task performance in depressed patients prior to antidepressant treatment
Trial: 9203932
Drug: Loxiglumide (CCK‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK‐A receptor antagonist) at 10 mg/kg/h
Trial: 9203932
Drug: Paired saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired saline infusion
Trial: 7869908
Drug: Delta TSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta TSA exceeding 10 mg/dL
Trial: 7869908
Drug: Delta TSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta TSA not exceeding 10 mg/dL
Trial: 2081793
Drug: Oral immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immune globulin preparation
Trial: 367576
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate with MER‐BCG
Trial: 367576
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate without MER‐BCG
Trial: 367576
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate (with or without MER‐BCG)
Trial: 31657981
Drug: Additional intrathecal
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional intrathecal therapy (two extra doses)
Trial: 31657981
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional intrathecal therapy
Trial: 25406858
Drug: Usual homecare
RxNorm normalized name: Welmedix Homecare Pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual homecare re‐ablement plus an enhanced program targeted at activities of daily living (ADL), delivered by an occupational therapist.
Trial: 25406858
Drug: Usual homecare
RxNorm normalized name: Welmedix Homecare Pro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual homecare re‐ablement (without routine occupational therapy input).
Trial: 22785005
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (O(2))
Trial: 21352267
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine ER 8 mg
Trial: 12153960
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 micro g once daily (n = 13)
Trial: 10089948
Drug: Oral fluoropyrimidines
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluoropyrimidines (o-FPs)
Trial: 30207807
Drug: HP 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 0.01% lotion
Trial: 30207807
Drug: HP 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 0.05% cream
Trial: 25877021
Drug: 10-mg intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg intramuscular metoclopramide prior to operation
Trial: 15219269
Drug: Budesonide/formoterol adjustable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol adjustable maintenance dosing (two inhalations bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inhalations once nocte or one inhalation bid if symptoms were controlled)
Trial: 15219269
Drug: Budesonide/formoterol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol fixed maintenance dosing (two inhalations bid)
Trial: 11690735
Drug: Gabapentin 1800
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1800 mg/day and 2400 mg/day
Trial: 1546861
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks
Trial: 25911824
Drug: Domperidone suspension
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone suspension (0.3 mg x kg(-1) x d(-1), tid, orally 30 minutes before meals)
Trial: 17917611
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg oral capsules three times daily for 4 weeks
Trial: 17917611
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg oral capsules
Trial: 12839718
Drug: Modified Danger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Danger Ideation Reduction Therapy (DIRT)
Trial: 29959110
Drug: Qualitative-only analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative-only analysis for drug question (n=58)
Trial: 29959110
Drug: NLP analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP analysis for drug question
Trial: 29959110
Drug: Qualitative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative and NLP-augmented analysis for drug question
Trial: 29959110
Drug: NLP-only approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP-only approach for drug question
Trial: 29959110
Drug: Qualitative-only approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative-only approach for drug question
Trial: 29959110
Drug: Qualitative analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative analysis followed by qualitative- or NLP-augmented analysis for drug question
Trial: 29959110
Drug: NLP analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP analysis followed by qualitative analysis for drug question
Trial: 24141698
Drug: palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palonosetron 0.25 or 0.75 mg
Trial: 24141698
Drug: palonosetron 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palonosetron 0.75 mg
Trial: 22711895
Drug: Intranasal ROX-828
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ROX-828 (31.5 mg ketorolac tromethamine/200 µL, containing 6% of lidocaine)
Trial: 22711895
Drug: Intranasal ROX-828
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ROX-828
Trial: 19226292
Drug: MgSO(4)/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO(4)/L
Trial: 12908666
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment added to existing treatment options
Trial: 12908666
Drug: Existing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing treatment options
Trial: 10821991
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral carvedilol
Trial: 17033273
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg carvedilol
Trial: 3899771
Drug: Sustained-release clomipramine
RxNorm normalized name: clomipramine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release clomipramine (Anafranil SR) 75 mg once daily
Trial: 3899771
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of clomipramine (Anafranil) 75 mg once daily
Trial: 24820768
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (MgO) with H2 receptor antagonist (H2RA)
Trial: 24820768
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (MgO) with proton pump inhibitor (PPI)
Trial: 15975759
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy (IPEC) consisting of doxorubicin, 0.1mg/kg and cisplatin, 15 mg/m² per day for 5 consecutive days.
Trial: 10469101
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of pulsed CO2 laser followed by Q-switched alexandrite laser
Trial: 7563337
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 sterile solution
Trial: 7563337
Drug: Pediatric sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric sterile solution (placebo)
Trial: 22985205
Drug: CBT +
RxNorm normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBT + fluoxetine
Trial: 23375165
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (types 1:2:3 = 3:100:100 DU)
Trial: 23375165
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (types 1:2:3 = 1.5:50:50 DU)
Trial: 23375165
Drug: Vaccine C
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine C (types 1:2:3 = 0.75:25:25 DU)
Trial: 21441782
Drug: PHiD‐CV (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV (3 doses)
Trial: 21441782
Drug: PHiD‐CV (2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV (2-dose catch-up)
Trial: 19944004
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with no-updosing regimen
Trial: 19944004
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with traditional updosing approach
Trial: 16816491
Drug: C. pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. pen and gentamicin intravenously (IV), followed by oral amoxicillin
Trial: 16816491
Drug: amox-clav IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amox-clav IV, followed by oral amox-clav
Trial: 14594793
Drug: Intraperitoneal amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal amino acid solution (2 L, 1.1%)
Trial: 14594793
Drug: Intraperitoneal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal glucose solution (2.27%)
Trial: 10659979
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (900 mg/day)
Trial: 8362600
Drug: s.c. rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week
Trial: 8362600
Drug: s.c. rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. rIL-2 in combination with s.c. rIFN-alpha at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week
Trial: 2433307
Drug: Intravenous gammaglobulin
RxNorm normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gammaglobulin (IVGG) plus aspirin (ASA)
Trial: 20395260
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) Q5 (>5.1-6.9 mmol/L)
Trial: 20395260
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose (FPG) Q5e (5.8-6.9 mmol/L)
Trial: 18962988
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/day for 6 weeks
Trial: 15478314
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 valerate 2-4 mg/day
Trial: 15478314
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 50-100 microg/day
Trial: 11487675
Drug: Alteplase (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (2 mg per 2 mL)
Trial: 9777425
Drug: Intramuscular cyanocobalamin
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular cyanocobalamin injections
Trial: 8797622
Drug: Rectal temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal temperature
Trial: 3046651
Drug: Pre-operative prophylactic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative prophylactic dose of a combination of crystalline penicillin and chloramphenicol
Trial: 30341773
Drug: 10% CPP-ACP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% CPP-ACP crème applied three times daily
Trial: 27849566
Drug: Sacubitril/valsartan 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 400 mg once daily for 4 weeks
Trial: 27849566
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg once daily for 4 weeks
Trial: 26306691
Drug: Patient-centered systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered systematic drug review intervention by trained primary care physicians (PCPs)
Trial: 21227601
Drug: Days of
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days of use during treatment
Trial: 16480471
Drug: 2-chloroprocaine 30
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-chloroprocaine 30 mg/ml
Trial: 16480471
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg/ml with 5 microg/ml epinephrine
Trial: 12900689
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg x kg‐1 of caffeine in the AM and 2.5 mg x kg‐1 of caffeine in the PM (trial A)
Trial: 12900689
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg x kg‐1 of caffeine in the AM and placebo in the PM (trial C)
Trial: 12900689
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the AM and 5 mg x kg‐1 of caffeine in the PM (trial D)
Trial: 11180196
Drug: Uroxin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uroxin (400 mg)
Trial: 11180196
Drug: Noroxin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noroxin (400 mg)
Trial: 9420044
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole (200 mg) administered as four 1-hour infusions on days 1-2, followed by daily 1-hour infusions of 200 mg from days 3-7.
Trial: 9420044
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution (200 mg once daily) after i.v. treatment.
Trial: 9420044
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole solution (200 mg twice daily) after i.v. treatment.
Trial: 9420044
Drug: Intravenous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment phase compared to oral treatment phase.
Trial: 8237748
Drug: Theophylline (aminophylline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (aminophylline, mean concentration 16.1 mg/L)
Trial: 29033381
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg intravenous infusion once yearly for 2 years
Trial: 22621776
Drug: Intranasal BDP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal BDP HFA 80 μg
Trial: 22621776
Drug: Intranasal BDP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal BDP HFA 320 μg
Trial: 22621776
Drug: Orally inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled BDP HFA 320 μg
Trial: 22621776
Drug: Intranasal BDP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal BDP HFA 320 μg vs Orally inhaled BDP HFA 320 μg
Trial: 22621776
Drug: Intranasal BDP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal BDP HFA 80 μg vs 320 μg
Trial: 19880495
Drug: EBV-specific cytotoxic
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBV-specific cytotoxic T lymphocytes (CTLs) treatment
Trial: 17655686
Drug: EZE/SIMVA 10/10-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/10-, 10/20-, 10/40-, or 10/80-mg
Trial: 17655686
Drug: SIMVA 10-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIMVA 10-, 20-, 40-, or 80-mg
Trial: 12235450
Drug: Atovaquone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone (250 mg daily) plus chloroguanide (100 mg daily)
Trial: 2686421
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg IV every 12 hours followed by 500 mg orally every 12 hours)
Trial: 2686421
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g IV every 8 to 12 hours)
Trial: 26311325
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders for each dose of medicine in addition to the standard of care.
Trial: 21546500
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride plus low-dose interleukin-2
Trial: 16950752
Drug: rhGH (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.4 mg/day for males, 0.6 mg/day for females) for 12 months
Trial: 16841668
Drug: Jinghua Weikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghua Weikang Capsule (JWC) high-dose 160 mg, 3 times per day for 14 days
Trial: 16841668
Drug: Jinghua Weikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghua Weikang Capsule (JWC) low-dose 80 mg, 3 times per day for 14 days
Trial: 16841668
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg, 3 times per day for 14 days (Control group)
Trial: 1836918
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms intradermal injection
Trial: 1836918
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms intramuscular injection